Search

Displaying results 5961 - 5970 of 7540 in total
  1. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    It is not indicated for use in humans in the US and is only available through veterinary clinics.

  2. Drug

    APT3111

    go.drugbank.com/drugs/DB06390
    Experimental

    APT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).

  3. Drug

    Isopropyl beta-D-thiogalactopyranoside

    go.drugbank.com/drugs/DB01862
    Experimental

    A non-metabolizable galactose analog that induces expression of the LAC operon.

  4. Drug

    NM-3

    go.drugbank.com/drugs/DB12818
    Investigational

    NM-3 has been used in trials studying the treatment of Neoplasms.

    Synonyms: NM-3
  5. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK.

  6. Drug

    Bizalimogene ralaplasmid

    go.drugbank.com/drugs/DB16113
    Investigational

    Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related

  7. Drug

    Oxametacin

    go.drugbank.com/drugs/DB13308
    Experimental

    Categories: Antiinflammatory and Antirheumatic Products, Non-Steroids
  8. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development … [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro

  9. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). … Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.

  10. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).